Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Cardiovascular

Byvalson (nebivolol and valsartan) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of hypertension, to lower blood pressure

Edarbi® (azilsartan medoxomil) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated for the treatment of hypertension to lower blood pressure

Norliqva® (amlodipine) oral solution

Approval Date: Feb 2022

Note: New Product

A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.

Aspruzyo Sprinkle (ranolazine) extended release granules

Approval Date: Feb 2022

Note: New Product

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

Medication Name

Approval Date

Category

Description

Byvalson (nebivolol and valsartan) tablets

Sep 2022

Indicated for the treatment of hypertension, to lower blood pressure

Note: First-Time Generic

Edarbi® (azilsartan medoxomil) tablets

Jul 2022

Indicated for the treatment of hypertension to lower blood pressure

Note: First-Time Generic

Norliqva® (amlodipine) oral solution

Feb 2022

A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.

Note: New Product

Aspruzyo Sprinkle (ranolazine) extended release granules

Feb 2022

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

Note: New Product
lockenvelopephone-handsetmenucross-circle